Stable gene transfer into hepatocytes has been proposed to compensate for genetic deficiencies that affect liver function, or to deliver diffusible factors into the circulation. This strategy can be achieved using retroviral vectors; however, cell division must occur. We describe a simple and reproductive method that enables the induction of hepatocyte replication in a controlled fashion, thus allowing an efficient in vivo retroviral liver transduction that is applicable to mouse models of human genetic disorders. The approach is based on liver susceptibility to apoptosis via the Fas/CD95 pathway. We show that, 4 days following a single Fas agonist antibody (JO2) injection, hepatocyte replication occurs, the intensity of which is correlated with the level of the induced hepatic cytolysis. This treatment enables in vivo liver transduction, and its efficiency also correlates with the level of hepatic cytolysis. When recombinant retroviral vectors were infused intravenously during the period of hepatocyte replication, 15.4% ؎ 1.7% of the hepatocytes were transduced, reaching up to 32.5%. (HEPATOLOGY 2001;33: 10-15.)The liver is a target organ for gene-therapy approaches, because it is the site of many metabolic disorders and because hepatocytes can be targeted to secrete proteins in the blood stream. Gene-delivery systems able to integrate the transgene into the hepatocyte genome are required to achieve a longterm therapeutic effect. However, their efficacy in mouse models of human disorders has been limited by a low level of liver transduction. For example, adeno-associated virus requires high numbers of viral particles to stably integrate into less than 5% of the mouse hepatocytes after direct in vivo intraportal injection. 1-4 Additionally, adeno-associated virus vectors induce an immune response that may subsequently diminish the efficacy of repeated administrations. 5 More recently, the injection of naked DNA associated with a transposase has been shown to allow stable gene expression in less than 5% of the hepatocytes. 6 Among the integrative vectors, retroviral vectors are the best characterized. However, 2 elements have limited the extensive use of retroviral vectors on mouse models of genetic disorders: 1) the need for high viral titers; and 2) the necessity to induce hepatocyte proliferation for transgene integration. The commonly used protocols to induce hepatocyte proliferation involve either a surgical procedure, such as a two-thirds hepatectomy, 7-11 or the injection of cytotoxic factors. [11][12][13] However, these strategies are based on major surgical procedures or require a high dose of injected retroviral vector.New approaches combining growth factor pretreatment, such as hepatocyte growth factor or keratinocyte growth facAbbreviations: MOI, multiplicity of infection; PH, partial hepatectomy; ALT, alanine transaminase; -gal, -galactosidase; bfu, blue-forming unit; BrdU, 5-bromo-2Ј-deoxyuridine.From the 1 U.129 INSERM, ICGM,